By Dhirendra Tripathi
Investing.com – Shares of Moderna (NASDAQ:MRNA) and BioNTech (NASDAQ:BNTX) slipped in Thursday’s trade after the CDC said the number of cases of a heart inflammation condition in 16-to-24-year-olds was higher than expected after they received their second dose of Pfizer Inc (NYSE:PFE) or Moderna’s Covid-19 vaccines.
Moderna was down 2.5% while BioNTech fell 1.5%. Pfizer was still holding up around its gain of 1% after slipping below it for some time.
BioNTech and Pfizer have a tie-up to make and market the vaccine, built on the former’s mRNA technology.
The U.S. Centers for Disease Control and Prevention cited preliminary data from its vaccine safety monitor system while disclosing the findings.
There have been 275 reported cases of myocarditis or pericarditis, which are inflammation conditions of the heart, in people ages 16 to 24 as of May 31, CNBC reported. This was according to a CDC presentation prepared for a U.S. Food and Drug Administration advisory panel meeting Thursday.